Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Legal and Finance
  • Published:

Syndication—value in numbers

Nature Biotechnology volume 20, pages BE54–BE56 (2002)Cite this article

Killu Tougu Sanborn explains why venture capitalists prefer to invest as part of a syndicate, and what benefits this offers startups

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. principal at IngleWood Ventures, San Diego, CA

    Killu Tougu Sanborn

Author notes

  1. which invests in early-stage biotechnology and medical technology companies, primarily in Southern California. Areas of funding include biopharmaceuticals, drug discovery tools, medical devices and diagnostics, and healthcare information technology

    Authors
    1. Killu Tougu Sanborn
      View author publications

      Search author on:PubMed Google Scholar

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Sanborn, K. Syndication—value in numbers. Nat Biotechnol 20 (Suppl 6), BE54–BE56 (2002). https://doi.org/10.1038/nbt0602supp-BE54

    Download citation

    • Issue date:

    • DOI: https://doi.org/10.1038/nbt0602supp-BE54

    Search

    Advanced search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing